Beam Therapeutics Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Evans
- Full Time Employees
- 540
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 238 Main Street Cambridge MA United States of America 02142
- IPO Date
- Feb 6, 2020
- CIK
- 0001745999
- Website
- beamtx.com
- Similar Companies
- Business
- Beam Therapeutics Inc. (Nasdaq: BEAM) develops precision genetic medicines through proprietary base editing technologies that enable targeted single-nucleotide changes in DNA without double-strand breaks; core pipeline programs include BEAM-101 for sickle cell disease and beta-thalassemia, BEAM-302 for severe alpha-1 antitrypsin deficiency (AATD), BEAM-201 for refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), BEAM-301 for glycogen storage disease 1a (GSDIa), and BEAM-103/104 for additional genetic diseases; delivery platforms encompass electroporation, non-viral lipid nanoparticles, and viral modalities. Founded in 2017 and headquartered at 238 Main Street in Cambridge, Massachusetts, with a manufacturing facility in Research Triangle Park, North Carolina, the company targets serious diseases in hematology, liver, oncology, and genetic disease segments, primarily in the United States. Recent developments include FDA clearance for the BEAM-301 IND in GSDIa, dosing of the first patient in the BEAM-302 Phase 1/2 trial for AATD, enrollment of over 20 patients with six dosed in the BEACON Phase 1/2 trial for BEAM-101 in severe sickle cell disease, acquisition of an early-stage life sciences company for $14.5 million on July 1, 2025, and holding 75 million shares in collaborator Orbital Therapeutics, which Bristol Myers Squibb agreed to acquire in October 2025 for $1.5 billion.
Company News
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Squeeze Watch: 10 Stocks With Over 33% Short Interest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Engineers Gate Manager LP Reduces Stock Holdings in Beam Therapeutics Inc. $BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
These 10 Stocks Are Squeeze Candidates Waiting to Happen